Spacelabs Medical
This article was originally published in The Gray Sheet
Executive Summary
Patient monitoring firm expects $30-50 mil. in incremental revenues over the next five years as a result of CMS' Oct. 17 favorable reimbursement decision for ambulatory blood pressure monitoring (ABPM) for the diagnosis of suspected white coat hypertension, according to an Oct. 25 announcement. Separately, the firm reports third-quarter (ended Sept. 29) revenue of $57 mil., down from $65.2 mil. in the comparable period in 2000, due in part to "the global economic and political environment"